Jeffrey W Taub

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8247912/publications.pdf

Version: 2024-02-01

125	5,028	81900	102487
papers	citations	39 h-index	66 g-index

127	127	127	5675
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, The, 2010, 11, 543-552.	10.7	514
2	A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood, 2006, 107, 4606-4613.	1.4	270
3	Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood, 2011, 118, 6752-6759.	1.4	182
4	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clinical Cancer Research, 2016, 22, 4440-4451.	7.0	176
5	Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL. Cell, 2012, 150, 575-589.	28.9	136
6	A delicate balance â€“ The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochemical Pharmacology, 2019, 162, 250-261.	4.4	135
7	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 6815-6826.	7.0	115
8	GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia. Journal of the National Cancer Institute, 2005, 97, 226-231.	6.3	107
9	High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood, 2002, 99, 2992-2996.	1.4	104
10	Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy, 2017, 2, 17012.	17.1	104
11	Down syndrome, drug metabolism and chromosome 21. Pediatric Blood and Cancer, 2005, 44, 33-39.	1.5	99
12	Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood, 2006, 107, 1570-1581.	1.4	99
13	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy, 2020, 5, 288.	17.1	98
14	Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood, 2004, 104, 1588-1589.	1.4	95
15	Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell, 2019, 36, 123-138.e10.	16.8	93
16	Down Syndrome and Malignancies: A Unique Clinical Relationship. Journal of Molecular Diagnostics, 2009, 11, 371-380.	2.8	86
17	RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood, 2009, 114, 2744-2752.	1.4	81
18	The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines. Cancer Research, 2004, 64, 728-735.	0.9	78

#	Article	IF	Citations
19	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. PLoS ONE, 2013, 8, e79106.	2.5	76
20	Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reducedâ€dose chemotherapy on Children's Oncology Group trial A2971. Cancer, 2012, 118, 4806-4814.	4.1	72
21	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5499-5510.	7.0	71
22	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Childrenâ€™s Oncology Group AAML0431 trial. Blood, 2017, 129, 3304-3313.	1.4	71
23	Mindfulness and dynamic functional neural connectivity in children and adolescents. Behavioural Brain Research, 2018, 336, 211-218.	2.2	68
24	A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. Cancer Cell, 2018, 34, 707-723.e7.	16.8	68
25	MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood, 2015, 125, 1292-1301.	1.4	66
26	Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood, 2009, 114, 2753-2763.	1.4	65
27	Transcriptional regulation of the human cystathionine Î²-synthase â^'1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. Biochemical Journal, 2001, 357, 97-105.	3.7	64
28	Cardiomyopathy in Children With Down Syndrome Treated for Acute Myeloid Leukemia: A Report From the Children's Oncology Group Study POG 9421. Journal of Clinical Oncology, 2008, 26, 414-420.	1.6	59
29	Association between prenatal pesticide exposures and the generation of leukemia-associated T(8;21). Pediatric Blood and Cancer, 2007, 49, 624-628.	1.5	57
30	Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes. Neuropsychology Review, 2018, 28, 123-175.	4.9	55
31	Increased Frequency of Expression of Elevated Dihydrofolate Reductase in T-Cell Versus B-Precursor Acute Lymphoblastic Leukemia in Children. Blood, 1997, 90, 578-589.	1.4	54
32	Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Haematologica, 2019, 104, 2225-2240.	3.5	53
33	Acute leukemias in children with Down syndrome. Molecular Genetics and Metabolism, 2012, 107, 25-30.	1.1	51
34	Transcriptional regulation of the cystathionine-Î²-synthase gene in Down syndrome and nonâ€“Down syndrome megakaryocytic leukemia cell lines. Blood, 2003, 101, 1551-1557.	1.4	46
35	Relationship of Chromosome 21 and Acute Leukemia in Children With Down Syndrome. The American Journal of Pediatric Hematology/oncology, 2001, 23, 175-178.	1.3	45
36	Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2020, 5, 17.	17.1	43

#	Article	IF	Citations
37	Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Scientific Reports, 2017, 7, 41950.	3.3	42
38	Inhibition of <scp>XPO</scp>1 enhances cell death induced by <scp>ABT</scp>â€199 in acute myeloid leukaemia via Mclâ€1. Journal of Cellular and Molecular Medicine, 2018, 22, 6099-6111.	3.6	42
39	CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. Journal of Hematology and Oncology, 2014, 7, 53.	17.0	41
40	Characterization of autoantibodies against the platelet glycoprotein antigens IIb/IIIa in childhood idiopathic thrombocytopenia purpura. American Journal of Hematology, 1995, 48, 104-107.	4.1	40
41	Transcriptional regulation of the human cystathionine Î²-synthase â˜†1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. Biochemical Journal, 2001, 357, 97.	3.7	40
42	Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochemical Pharmacology, 2018, 148, 13-26.	4.4	38
43	The Prenatal Origin of Childhood Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2004, 45, 19-25.	1.3	37
44	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood, 2019, 134, 1227-1237.	1.4	37
45	Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine Î²-Synthase Gene by Differential Binding of Sp1/Sp3 to the â˜†1b Promoter. Journal of Biological Chemistry, 2001, 276, 43570-43579.	3.4	36
46	Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Molecular Oncology, 2015, 9, 409-421.	4.6	35
47	Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Oncotarget, 2016, 7, 34785-34799.	1.8	35
48	Satisfaction with support versus size of network: differential effects of social support on psychological distress in parents of pediatric cancer patients. Psycho-Oncology, 2016, 25, 551-558.	2.3	34
49	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells. Journal of Medicinal Chemistry, 2016, 59, 7974-7990.	6.4	33
50	Risk for leukemia in infants without down syndrome who have transient myeloproliferative disorder. Journal of Pediatrics, 2006, 148, 687-689.	1.8	32
51	Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biology and Therapy, 2015, 16, 1784-1793.	3.4	32
52	Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Letters, 2015, 356, 656-668.	7.2	32
53	Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells. PLoS ONE, 2013, 8, e76662.	2.5	32
54	Methotrexate Pharmacology and Resistance in Childhood Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1996, 21, 359-368.	1.3	29

#	Article	IF	Citations
55	Synergistic regulation of human cystathionine-Î²-synthase-1b promoter by transcription factors NF-YA isoforms and Sp1. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1579, 73-80.	2.4	29
56	Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochemical Pharmacology, 2020, 182, 114253.	4.4	29
57	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget, 2017, 8, 44295-44311.	1.8	29
58	Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatric Blood and Cancer, 2014, 61, 1767-1773.	1.5	28
59	Down Syndrome Preleukemia and Leukemia. Pediatric Clinics of North America, 2015, 62, 121-137.	1.8	26
60	Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget, 2017, 8, 6319-6329.	1.8	26
61	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers, 2020, 12, 2400.	3.7	26
62	Transcription factor GATA-1 and Down syndrome leukemogenesis. Leukemia and Lymphoma, 2006, 47, 986-997.	1.3	25
63	Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Review of Hematology, 2014, 7, 831-840.	2.2	24
64	The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica, 2021, 106, 1262-1277.	3.5	24
65	Self-Distancing Buffers High Trait Anxious Pediatric Cancer Caregivers Against Short- and Longer-Term Distress. Clinical Psychological Science, 2016, 4, 629-640.	4.0	22
66	The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer Journal, 2021, 11, 111.	6.2	22
67	Down Syndrome and the Transient Myeloproliferative Disorder: Why Is It Transient?. Journal of Pediatric Hematology/Oncology, 2002, 24, 6-8.	0.6	22
68	Children with hyperdiploid but not triple trisomy (+4,+10,+17) acute lymphoblastic leukemia have an increased incidence of extramedullary relapse on current therapies: A single institution experience. American Journal of Hematology, 2008, 83, 34-40.	4.1	21
69	Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood and Cancer, 2012, 59, 1245-1251.	1.5	21
70	Transcriptional Regulation of the Human Reduced Folate Carrier in Childhood Acute Lymphoblastic Leukemia Cells. Clinical Cancer Research, 2006, 12, 608-616.	7.0	19
71	Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome. Leukemia, 2019, 33, 2746-2751.	7.2	18
72	Unique clinical and biological features of leukemia in Down syndrome children. Expert Review of Hematology, 2010, 3, 175-186.	2.2	17

#	Article	IF	Citations
73	Overexpression of GATA1 Confers Resistance to Chemotherapy in Acute Megakaryocytic Leukemia. PLoS ONE, 2013, 8, e68601.	2.5	17
74	COVIDâ€19 and childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28400.	1.5	17
75	Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia . Cancer Management and Research, 2019, Volume 11, 3197-3213.	1.9	16
76	Understanding differences in the long-term psychosocial adjustment of pediatric cancer patients and their parents: an individual differences resources model. Translational Behavioral Medicine, 2019, 9, 514-522.	2.4	16
77	High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood, 2021, 138, 2337-2346.	1.4	16
78	Acute Megakaryoblastic Leukemia Without GATA1 Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. Journal of Clinical Oncology, 2011, 29, e230-e233.	1.6	15
79	Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia. American Journal of Translational Research (discontinued), 2016, 8, 3893-3902.	0.0	13
80	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	4.1	12
81	Down Syndrome and Acute Myeloid Leukemia. Advances in Experimental Medicine and Biology, 1999, , 409-414.	1.6	11
82	A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy. PLoS ONE, 2011, 6, e27486.	2.5	11
83	Pediatric cancer, posttraumatic stress and fear-related neural circuitry. International Journal of Hematologic Oncology, 2019, 8, IJH17.	1.6	10
84	7 Treatment of childhood acute myeloid leukaemia. Best Practice and Research: Clinical Haematology, 1996, 9, 129-146.	1.1	9
85	Incidence and outcomes of rare paediatric nonâ€hodgkin lymphomas. British Journal of Haematology, 2019, 184, 864-867.	2.5	9
86	Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431. Archives of Pathology and Laboratory Medicine, 2020, 144, 466-472.	2.5	9
87	â€œFLippingâ€•the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers, 2022, 14, 3398.	3.7	9
88	Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia. PLoS ONE, 2016, 11, e0161539.	2.5	8
89	Posttraumatic Stress Symptoms in Parents of Pediatric Cancer Patients: A Mediational Analysis. Journal of Traumatic Stress Disorders & Treatment, 2014, 03, .	0.3	8
90	Molecular and Cellular Correlates of Methotrexate Response in Childhood Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 1999, 35, 1-20.	1.3	7

#	Article	IF	Citations
91	What's up with down syndrome and leukemiaâ€A lot!. Pediatric Blood and Cancer, 2011, 57, 1-3.	1.5	7
92	Martial Arts-Based Therapy Reduces Pain and Distress Among Children with Chronic Health Conditions and Their Siblings. Journal of Pain Research, 2020, Volume 13, 3467-3478.	2.0	7
93	Exposure of Larval Zebrafish to the Insecticide Propoxur Induced Developmental Delays that Correlate with Behavioral Abnormalities and Altered Expression of hspb9 and hspb11. Toxics, 2019, 7, 50.	3.7	6
94	Emotionâ€related brain organization and behavioral responses to socioemotional stimuli in pediatric cancer survivors with posttraumatic stress symptoms. Pediatric Blood and Cancer, 2019, 66, e27470.	1.5	6
95	Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second â€œHitâ€in Leukemogenesis. Journal of Pediatric Hematology/Oncology, 2021, 43, e1241-e1243.	0.6	6
96	Improvement in Treatment Outcome and Identification of a New Prognostic Parameter in Down Syndrome Acute Myeloid Leukemia (DS-AML): Results of the Childrenâ€™s Oncology Group (COG) Phase III AAML0431 Trial. Blood, 2014, 124, 278-278.	1.4	6
97	The paradox of Myeloid Leukemia associated with Down syndrome. Biochemical Pharmacology, 2022, 201, 115046.	4.4	6
98	Factors in Improved Survival from Paediatric Cancer. Drugs, 1998, 56, 757-765.	10.9	5
99	Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. Targeted Oncology, 2019, 14, 351-364.	3.6	5
100	Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis. Annals of Hematology, 2021, 100, 1695-1700.	1.8	5
101	Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2019, 4, 44.	17.1	4
102	Slow Transcription of the 99a/let-7c/125b-2 Cluster Results in Differential MiRNA Expression and Promotes Melanoma Phenotypic Plasticity. Journal of Investigative Dermatology, 2021, 141, 2944-2956.e6.	0.7	3
103	Acute Megakaryoblastic Leukemia (AMKL) in Children without Down Syndrome.. Blood, 2009, 114, 482-482.	1.4	3
104	Down syndrome and megakaryocytic leukemia/transient myeloproliferative disorder: when does it begin?. Blood, 2003, 101, 4228-4228.	1.4	2
105	Ethosuximide-induced Thrombocytopenia: A Case Report. Journal of Pediatric Hematology/Oncology, 2019, 41, 420-421.	0.6	2
106	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3â€ITD AML. Pediatric Blood and Cancer, 2021, 68, e29278.	1.5	2
107	Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia. Blood, 2018, 132, 1361-1361.	1.4	2
108	Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells. Blood, 2015, 126, 1265-1265.	1.4	2

#	Article	IF	Citations
109	Leukemias in patients with Down syndrome. , 0, , 503-519.		1
110	Clinical Trial Enrollment is Associated With Improved Follow-up Rates Among Survivors of Childhood Cancer. Journal of Pediatric Hematology/Oncology, 2019, 41, e18-e23.	0.6	1
111	Delayed Granulocyte Colony-Stimulating Factor (G-CSF) Administration after Chemotherapy Reduces Total G-CSF Doses without Affecting Neutrophil Recovery in a Randomized Clinical Study in Children with Solid Tumors. Pediatric Hematology and Oncology, 2020, 37, 665-675.	0.8	1
112	Unusual clinical behavior of a very late retinoblastoma relapse in a patient with a germline RB mutation. Pediatric Blood and Cancer, 2021, 68, e29064.	1.5	1
113	Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells. Blood, 2015, 126, 2469-2469.	1.4	1
114	Author's reply to Ã–zsoylu. , 1996, 51, 328-328.		0
115	Down syndrome and leukemiaâ€"it's in the cards. Blood, 2004, 103, 2434-2434.	1.4	0
116	Down syndrome and leukemia: A model of leukemogenesis and cure. International Journal on Disability and Human Development, 2008, 7, .	0.2	0
117	Neonatal GATA1 mutant clones under the radar. Blood, 2013, 122, 3851-3853.	1.4	0
118	Etiology of Leukemia in Children with Down Syndrome. , 2016, , 89-108.		0
119	MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition. EBioMedicine, 2021, 70, 103488.	6.1	0
120	Minimal Residual Diseaseâ€"Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. Blood, 2009, 114, 16-16.	1.4	0
121	Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy. , 2010, , 109-122.		0
122	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. Blood, 2013, 122, 490-490.	1.4	0
123	Targeting The Wee1 Kinase With MK-1775 For Treatment Of Acute Myeloid Leukemia In The Down Syndrome Population. Blood, 2013, 122, 3836-3836.	1.4	0
124	Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo. Blood, 2016, 128, 1571-1571.	1.4	0
125	Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia. Blood, 2018, 132, 3936-3936.	1.4	0